Pharmaceutical Preparations
A source-attributed, AI-written analyst report for ANTX.
Every figure is drawn from public filings — the AI writes the analysis, never the numbers.
How the company returns cash to shareholders — from its latest annual SEC filings.
Annual figures from SEC filings · descriptive, not a dividend-safety rating or advice. Delayed data.
Daily OHLC · MA/MACD/RSI computed locally. Not investment advice.
Reference figures from the latest SEC filings.
| Market cap | $179.72M |
|---|---|
| 52-week range | $1.00 – $6.91 |
| Next earnings | Aug 6, 2026 |
Figures from SEC filings · delayed prices · for reference only · not investment advice
Try one backtest free — see how the golden-cross signal performed on this stock.
Sign in to run a free backtestHistorical statistic over past daily data — how this rule behaved before, not a prediction or advice.
Trailing return vs the S&P 500 (SPY) — positive means it outperformed the market.
Trailing price performance vs SPY — a disclosed historical statistic, not a forecast or advice. Delayed data.
How the price has historically moved around past earnings announcements.
A ~2-session move spanning each earnings date — a disclosed historical statistic, not a forecast or advice. Delayed data.
Percentile rank vs Tickwind’s tracked universe — higher = stronger on that factor.
Percentile rank vs Tickwind’s tracked universe. The letter grades are a plain relabeling of these descriptive percentiles; the headline Quant Rating is a disclosed mechanical mapping of the composite percentile — a relative quantitative signal, not personalized investment advice. Delayed data.
Two published academic scores computed from SEC filings — itemized, descriptive, not a rating.
Computed from SEC XBRL filings via published academic formulas (Piotroski 2000; Altman 1968). Zone names are the papers’ published band labels. Descriptive — not a rating, prediction, or investment advice.
Average return by calendar month over the available years.
Historical average monthly returns — a disclosed statistic, not a forecast or advice. Delayed data.
Log in to track ANTX and save links
Keep a watchlist and clip posts from anywhere — free.
Latest SEC filings and headlines for AN2 Therapeutics, Inc. (ANTX).
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Yahoo · Jun 4, 2026
AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates
Benzinga · Jun 4, 2026
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Benzinga · Jun 4, 2026
Figures from SEC filings · delayed prices · for reference only · not investment advice